Infectologia
Editorial | COVID está conturbando carreiras científicas pelo mundo.
15 Nov, 2021 | 13:59hCOVID is disrupting scientific careers around the world – Nature
Ver também:
Scientists count the career costs of COVID – Nature
Potentially long-lasting effects of the pandemic on scientists – Nature
O que influencia as respostas das pessoas às mensagens de saúde pública para o controle de riscos e prevenção de doenças infecciosas? Uma breve revisão sistemática das evidências e recomendações.
15 Nov, 2021 | 13:57h
Comentário no Twitter
COVID-19 messages should:
1) be developed with communities
2) address uncertainty immediately + with transparency
3) focus on unifying messages from sources
4) frame messages aimed at increasing understanding, social responsibility + ind control https://t.co/faxtAgngAI— Caroline Tomes MFPH (@carotomes) November 12, 2021
De acordo com estudo, vacinas contra SARS-CoV-2 são seguras e imunogênicas na maioria das pessoas com câncer.
15 Nov, 2021 | 13:56hComunicado de imprensa: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School
Estudo original: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology
Comentário do autor no Twitter (fio – clique para saber mais)
The CANVAX study is out in @JCO_ASCO! https://t.co/WKrU6dQIEB
Grateful to >1000 CANVAX participants, study leads ( @JustinGainor, @MGHPathology, @BalazsLab) and so many co-authors incl. @arthur_kim_ID, @KimberlyBlumen1, @joanhowMD, @dradityabardia
Much more to come!— Vivek Naranbhai, MD, PhD, DPhil (@vivek_naranbhai) November 10, 2021
#AHA21 – Estudo randomizado | Entre crianças e adolescentes submetidos a rastreamento ecocardiográfico e diagnosticados com doença cardíaca reumática latente, antibioticoprofilaxia secundária com penicilina G benzatina por 2 anos foi associada com redução da progressão ecocardiográfica (0,8 vs, 8,2% no grupo controle).
15 Nov, 2021 | 13:53hSecondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentários:
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology
Comentários no Twitter
One of most important studies ever Rheumatic Heart Disease @NEJM https://t.co/U8FuNHLqCJ RCT evidence 2ry prophylaxis reduces progression latent RhD pic.twitter.com/UycTElr7QM
— Michael Marks (@dr_michaelmarks) November 13, 2021
Penicillin slowed the devastating impact of rheumatic heart disease among children in Uganda. Findings of a large-scale, randomized controlled trial were completed in Uganda. Group A strep underlies rheumatic heart disease. New England Journal of Medicine https://t.co/1PKFJ12FvC
— delthia ricks 🔬 (@DelthiaRicks) November 13, 2021
Estudo randomizado | BBV152 (vacina indiana COVAXIN) tem uma eficácia geral de 77,8% contra Covid-19 sintomática em adultos.
12 Nov, 2021 | 13:51hComentário convidado: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet
Conteúdo relacionado: WHO issues emergency use approval for India’s Covaxin.
Comentário no Twitter
NEW—Interim data from a phase 3 trial of #BBV152, a COVID-19 vaccine developed in India, suggests it is safe and two doses offer 77.8% protection against symptomatic #COVID19. https://t.co/QWtz0AWd1X
— The Lancet (@TheLancet) November 11, 2021
Controle de infecção na UTI: diretrizes de consenso de especialistas para SARS-CoV-2 utilizando o método Delphi.
12 Nov, 2021 | 13:49h
Comentário da autora no Twitter (fio – clique para saber mais)
Honoured to lead this Delphi on Infection Control in ICU for SARS-CoV-2 with global experts https://t.co/39NTHgfyZR @Drnasap @ElieAzoulay5 @jigidivatia @AlhazzaniW @NaomiHammond @criticcaredoc @YaseenarabiYa @Laura_Evans_206 @FlaviaSepsis @AndersPerner @jlvincen @TheLancetInfDis pic.twitter.com/RWw6vXcHb0
— Sheila Myatra (@SheilaMyatra) November 11, 2021
Mortes de crianças e jovens na Inglaterra após infecção por SARS-CoV-2 durante o 1º ano da pandemia – “Ao todo, 99,995% das crianças e jovens com teste positivo para SARS-CoV-2 sobreviveram.”
12 Nov, 2021 | 13:48hConteúdo relacionado:
Study: Children and young people remain at low risk of COVID-19 mortality
Comentários no Twitter
Just published @NatureMedicine
An in-depth analysis of the 25 children who died from Covid in England during the 1st year of the pandemichttps://t.co/QK3gk1BXy5
Great that 99.995% of children w/ a positive test survived (not what is driving the need for 💉in kids) pic.twitter.com/moXKl8ysmA— Eric Topol (@EricTopol) November 11, 2021
A clinical review of all pediatric deaths in England from March 2020 to February 2021 attributes 25 deaths to SARS-CoV-2 infection and identifies risk factors to guide interventions, according to a @NatureMedicine article. https://t.co/Bpjhf5sgow pic.twitter.com/v24Zf9CsXK
— Nature Portfolio (@NaturePortfolio) November 11, 2021
Aumento da imunidade às vacinas contra COVID-19 – “Novos estudos destacam os benefícios imunológicos dos reforços da vacina contra COVID-19, mas ainda restam questões sobre como fazer o melhor uso de suprimentos globais limitados.”
12 Nov, 2021 | 13:46hBoosting immunity to COVID-19 vaccines – Nature Medicine
Mapa | O mundo segundo a cobertura vacinal contra Covid.
12 Nov, 2021 | 13:43hThe world according to covid vaccine coverage – The BMJ
Comentário no Twitter
A year since the first covid vaccines were announced, rollouts are under way all over the world—to differing degrees.
This map shows the percentage of national population to have received two doses of covid vaccinehttps://t.co/rIU3qeWXIK @munkeatlooi pic.twitter.com/zZHr1XXBe8
— The BMJ (@bmj_latest) November 11, 2021
Vigilância global, pesquisa e colaboração necessárias para aprimorar a compreensão e o tratamento da “long COVID”.
12 Nov, 2021 | 13:42hConteúdos relacionados:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)


